SEC Comment Letter 0000000000-26-002062 to MYRIAD GENETICS INC (MYGN)

MYRIAD GENETICS INC
Date: Feb. 27, 2026 · CIK: 0000899923 · Accession: 0000000000-26-002062

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-293681

Date

February 27, 2026

Author

Division of

Form

UPLOAD

Company

MYRIAD GENETICS INC

Letter

Re: Myriad Genetics, Inc. Registration Statement on Form S-3 Filed February 24, 2026 File No. 333-293681 Dear Samraat S. Raha:

February 27, 2026

Samraat S. Raha President and Chief Executive Officer Myriad Genetics, Inc. 322 North 2200 West Salt Lake City, UT 84116

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Chris Edwards at 202-551-6761 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Daniel T. Kajunski, Esq.

Show Raw Text

<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
                                                           February 27, 2026

Samraat S. Raha
President and Chief Executive Officer
Myriad Genetics, Inc.
322 North 2200 West
Salt Lake City, UT 84116

       Re: Myriad Genetics, Inc.
           Registration Statement on Form S-3
           Filed February 24, 2026
           File No. 333-293681
Dear Samraat S. Raha:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Chris Edwards at 202-551-6761 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:    Daniel T. Kajunski, Esq.
</TEXT>
</DOCUMENT>

SecProbe.io